Corvus Pharmaceuticals Balance Sheet
NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corvus Pharmaceuticals financial position
At the end of fiscal 2025, Corvus Pharmaceuticals reported total assets of $71.1 million, up 3.2% from a year earlier against total liabilities of $9.9 million. Shareholders' equity stood at $61.2 million, or 86.1% of assets. The company held $4.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.21, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Corvus Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20212022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 4.58M | 8.74M | 12.62M | 13.16M | 63.46M | 16.45M | 5.15M | 39.20M | 45.11M | 5.05M |
| Short-Term Investments | 52.17M | 43.22M | — | — | — | — | — | — | — | — |
| Receivables | 37.00K | 75.00K | 26.00K | 588.00K | — | — | — | — | — | — |
| Total Current Assets | 58.21M | 54.41M | 27.96M | 43.66M | 71.31M | 45.34M | 79.34M | 115.59M | 91.23M | 136.03M |
| Property, Plant & Equipment | 220.00K | 151.00K | 236.00K | 353.00K | 451.00K | 906.00K | 1.46M | 2.18M | 2.67M | 3.25M |
| Total Assets | 71.12M | 68.91M | 45.55M | 68.24M | 109.45M | 85.53M | 83.65M | 118.23M | 94.78M | 140.15M |
| Accounts Payable | 2.49M | 2.58M | 1.52M | 1.98M | 1.56M | 3.47M | 2.45M | 2.00M | 3.45M | 1.90M |
| Total Current Liabilities | 9.38M | 35.40M | 6.87M | 10.75M | 9.69M | 12.15M | 10.22M | 7.03M | 8.97M | 5.94M |
| Total Liabilities | 9.91M | 36.34M | 6.87M | 12.13M | 12.29M | 13.38M | 12.54M | 7.90M | 9.94M | 7.35M |
| Shareholders' Equity | 61.20M | 32.57M | 38.68M | 56.12M | 97.16M | 72.15M | 71.11M | 110.34M | 84.83M | 132.80M |
| Retained Earnings | -412.29M | -397.01M | -334.72M | -307.69M | -266.38M | -223.14M | -217.15M | -170.47M | -123.53M | -67.87M |
| Net Cash (Debt) | 56.75M | 51.96M | 12.62M | 13.16M | 63.46M | 16.45M | 5.15M | 39.20M | 45.11M | 5.05M |
| Shares Outstanding | 74.70M | 67.90M | 49.04M | 46.55M | 46.55M | 28.37M | 27.95M | 29.32M | 21.04M | 20.92M |
This table shows 10 annual periods of Corvus Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CRVS's reporting calendar. What is a balance sheet?